Canine Arthritis Market: Market Size & Forecast 2026

Canine arthritis is one of the most prevalent chronic conditions in dogs, with osteoarthritis affecting an estimated one in five adult dogs and a substantially higher share of senior animals. The market encompasses prescription anti-inflammatory drugs (NSAIDs and corticosteroids), disease-modifying osteoarthritis drugs (DMOADs), joint injections, physical therapy, surgical interventions, and a fast-growing nutraceutical segment. Across the major industry forecasts reviewed, the market is broadly valued in the USD 3.4-3.9 billion range for 2025, reflecting strong double-digit scale but some variation in how narrowly or broadly each report defines its scope.

• •Estimated 2025 market value: approximately USD 3.44 billion, growing at around 6.2% annually.
• •Osteoarthritis is the dominant indication, accounting for the majority of treated cases in dogs over seven years old.
• •Canines represent the largest sub-segment within the broader companion animal arthritis market, holding roughly 59.5% share of companion-animal osteoarthritis spending.

The most consistent growth lever is the humanization of pets, which has shifted dogs from property status toward family-member status and is steadily increasing per-animal healthcare expenditure. A growing senior-dog population, particularly in North America and Western Europe, is expanding the prevalence base for chronic joint disease. At the same time, advances in diagnostics (digital radiography, CT, and arthroscopy) and the availability of more sophisticated therapeutic options are pulling previously untreated cases into the formal care system.

• •Rising pet ownership and increased willingness to spend on veterinary specialty care.
• •Aging canine population and growing breed predisposition to joint disorders.
• •Improved diagnostic imaging and earlier veterinary intervention expanding the addressable patient pool.

By treatment type, the market is typically divided into pharmaceuticals (NSAIDs, DMOADs, biologics and monoclonal antibodies), nutraceuticals and supplements, and devices and surgical procedures, with pharmaceuticals accounting for the largest share. By distribution, sales flow through veterinary hospitals and clinics, retail pharmacies, and increasingly online channels. Geographically, North America leads on revenue per case, while Asia-Pacific is consistently identified as the fastest-growing region as middle-class pet ownership expands in China, Japan, and India.

• •Pharmaceuticals dominate by treatment type; nutraceuticals are the fastest-growing sub-category.
• •North America holds the largest revenue share, supported by advanced veterinary infrastructure and high pet insurance penetration.
• •Asia-Pacific is the fastest-growing region, driven by rising pet ownership and modernization of veterinary practice.

What are the recent trends and outlook?

The most notable clinical trend is the shift toward biologics and monoclonal antibody therapies, which offer targeted pain relief with fewer systemic side effects than traditional NSAIDs. Regenerative approaches, including autologous platelet-rich plasma and stem-cell therapy, are moving from specialty referral centers into broader practice, supported by a growing evidence base. Digital health tools, including wearable activity monitors and telemedicine platforms, are also beginning to influence how arthritis is monitored and managed between clinic visits, pointing toward a more data-driven, longitudinal model of canine joint care.

• •Monoclonal antibodies (e.g., bedinvetmab) are gaining share as a safer long-term alternative to NSAIDs for chronic pain.
• •Regenerative therapies such as platelet-rich plasma and stem-cell treatment are emerging as adjunct options in specialty practice.
• •Wearable activity monitors and tele-consultation are supporting earlier detection and ongoing management of osteoarthritis.